TY - JOUR T1 - Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease JF - medRxiv DO - 10.1101/2020.06.16.20133157 SP - 2020.06.16.20133157 AU - Petra Mlcochova AU - Dami Collier AU - Allyson Ritchie AU - Sonny M. Assennato AU - Myra Hosmillo AU - Neha Goel AU - Bo Meng AU - Krishna Chatterjee AU - Vivien Mendoza AU - Nigel Temperton AU - Leo Kiss AU - Leo C. James AU - Katarzyna A. Ciazynska AU - Xiaoli Xiong AU - John AG Briggs AU - James Nathan AU - Federica Mescia AU - Hongyi Zhang AU - Petros Barmpounakis AU - Nikos Demeris AU - Richard Skells AU - Paul A. Lyons AU - John Bradley AU - Steven Baker AU - Jean Pierre Allain AU - Kenneth GC Smith AU - Ian Goodfellow AU - Ravindra K. Gupta Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/26/2020.06.16.20133157.abstract N2 - Background Rapid COVID-19 diagnosis in hospital is essential for patient management and identification of infectious patients to limit the potential for nosocomial transmission. The diagnosis of infection is complicated by 30-50% of COVID-19 hospital admissions with nose/throat swabs testing negative for SARS-CoV-2 nucleic acid, frequently after the first week of illness when SARS-CoV-2 antibody responses become detectable. We assessed the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease in the emergency department.Methods We developed (i) an in vitro neutralization assay using a lentivirus expressing a genome encoding luciferase and pseudotyped with spike (S) protein and (ii) an ELISA test to detect IgG antibodies to nucleocapsid (N) and S proteins from SARS-CoV-2. We tested two lateral flow rapid fingerprick tests with bands for IgG and IgM. We then prospectively recruited participants with suspected moderate to severe COVID-19 and tested for SARS-CoV-2 nucleic acid in a combined nasal/throat swab using the standard laboratory RT-PCR and a validated rapid POC nucleic acid amplification (NAAT) test. Additionally, serum collected at admission was retrospectively tested by in vitro neutralisation, ELISA and the candidate POC antibody tests. We evaluated the performance of the individual and combined rapid POC diagnostic tests against a composite reference standard of neutralisation and standard laboratory based RT-PCR.Results 45 participants had specimens tested for nucleic acid in nose/throat swabs as well as stored sera for antibodies. Using the composite reference standard, prevalence of COVID-19 disease was 53.3% (24/45). Median age was 73.5 (IQR 54.0-86.5) years in those with COVID-19 disease by our composite reference standard and 63.0 (IQR 41.0-72.0) years in those without disease. The overall detection rate against the composite reference standard was 79.2% (95CI 57.8-92.9%) for rapid NAAT, decreasing from 100% (95% CI 65.3-98.6%) in days 1-4 to 50.0% (95% CI 11.8-88.2) for days 9-28 post symptom onset. Correct identification of COVID-19 with combined rapid POC diagnostic tests was 100% (95CI 85.8-100%) with a false positive rate of 5.3-14.3%, driven by POC LFA antibody tests.Conclusions Combined POC tests have the potential to transform our management of COVID-19, including inflammatory manifestations later in disease where nucleic acid test results are negative. A rapid combined approach will also aid recruitment into clinical trials and in prescribing therapeutics, particularly where potentially harmful immune modulators (including steroids) are used.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04326387Funding StatementRKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). DAC is supported by a Wellcome PhD training Fellowship. This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit (CCTU). LCJ is supported by the MRC (UK; U105181010) and a Wellcome Investigator Award. JAGB is supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (ERC-CoG-648432 MEMBRANEFUSION), and the Medical Research Council (MC_UP_1201/16).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVIDx, NCT04326387 was approved by the East of England Essex Research Ethics Committee (REC ref: 20/EE/0109). Serum samples were obtained from patients attending Addenbrookes Hospital with a suspected or confirmed diagnosis of COVID19. Ethical approval was obtained from the East of England Cambridge Central Research Ethics Committee REC ref 17/EE/0025.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from the corresponding author ER -